ClinicalTrials.gg
CompletedNCT03916419Updated Oct 6, 2026Results posted

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

A Phase 2 interventional study of ViewRay MR-Linear Accelerator and Radiation therapy in Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Updated Oct 6, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine — 2 open to participants now, 5 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Washington University School of Medicine.

Enrollment
7th of 26
26 · median 18
Started
2019
with 2 others
Phase 2
9 of 30
none open now
Registered
21st of 30
by date

Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine, this one is the 7th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 2, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine, or all of them as a file.
02

Study summary

Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small cell lung cancer (NSCLC), this prospective, single-arm Phase II clinical trial with safety lead-in will test the feasibility and outcomes of this approach.

03

Conditions studied

  • Stage IIB Non-Small Cell Lung Cancer
  • Stage IIIA Non-small Cell Lung Cancer
  • Stage IIIB Non-small Cell Lung Cancer
  • Stage IIIC Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven diagnosis of non-small cell lung cancer.
  • Inoperable or patient has refused surgery
  • Clinical AJCC stage IIB or IIIA (AJCC, 8th ed.) with plans to be treated with concurrent chemoradiotherapy.

    • Recurrent non-small cell lung cancer is allowed, provided the intent of the current treatment is curative and there has been no prior radiation to the thorax (except prior SBRT per the protocol)
    • Prior chemotherapy, immunotherapy, or targeted therapy is permitted as long as patients have recovered from prior toxicities to grade ≤ 1
    • Clinical AJCC stage IIIB with plans to be treated with concurrent chemoradiotherapy are eligible if any of the following apply: (1) T3N2M0, (2) T4N2M0 (with T4 by size criteria (> 7 cm); T4 due to invasion or nodules in other ipsilateral lobe are excluded), (3) T1-2N3M0 where N3 disease is confined to no more than 2 contiguous nodal stations in the contralateral mediastinum. N3 disease with either contralateral hilar adenopathy, multistation contralateral mediastinal adenopathy that is either non-contiguous or >2 contiguous nodal stations, or any scalene or supraclavicular adenopathy are not eligible.
    • Clinical AJCC stage IIIC (T3-4N3M0) are eligible if N3 disease is confined to no more than 2 contiguous nodal stations in the contralateral mediastinum as above and, if applicable, T4 is due only to size >7 cm as above.
  • Appropriate stage for protocol entry based upon the following minimum diagnostic workup:

    • History/physical examination within 30 days prior to registration
    • FDG-PET/CT scan and CT chest with or without contrast for staging within 60 days prior to registration
    • MRI scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration
  • Zubrod Performance Status 0-2 within 30 days prior to registration.
  • Age ≥ 18 years.
  • CBC/differential obtained within 30 days prior to registration, with adequate bone marrow function defined as follows:

    • (ANC) ≥ 1,500 cells/mm3
    • ≥ 100,000 cells/mm3
    • ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)
  • and ALT ≤ 1.5 within 30 days prior to registration.
  • Total ≤ 1.5 upper limit of normal within 30 days prior to registration.
  • Serum creatinine \< 1.5 mg/dL or calculated ≥ 50 mL/min within 30 days prior to registration estimated by the Cockcroft-Gault formula:

Creatinine Clearance (male) = [(140 - age) x (wt in kg)] [(Serum Creatinine mg/dl) x (72)] Creatinine Clearance (female) = 0.85 x Creatinine Clearance (male)

  • Peripheral neuropathy ≤ grade 1 at the time of registration.
  • Presence of measurable or evaluable disease by 1.1.
  • Negative serum or urine pregnancy test within 2 weeks prior to registration for women of .
  • Women of childbearing potential and male participants must agree to use a medically effective means of throughout their participation in the treatment phase of the study.
  • Able to understand and willing to sign an IRB-approved document. Patients without capacity to make an informed consent decision must have a legally authorized representative sign the IRB-approved informed consent document on their behalf.

Exclusion criteria

Exclusion Criteria:

  • Severe, active comorbidity, defined as follows:

    • Unstable angina, history of myocardial infarction and/or congestive heart failure requiring hospitalization within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
    • exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
    • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly . Protocol-specific requirements may also exclude immuno-compromised patients
  • Prior radiotherapy to the thorax. An exception can be made for prior stereotactic body radiation therapy (SBRT) if there is no overlap with the protocol PTV and OAR constraints can still be achieved with a composite plan.
  • Evidence of a concurrent primary , or any history of cancer.
  • Currently receiving any other agents.
  • Pregnant or breastfeeding.
  • Medical to receiving MRI imaging (including presence of a cardiac pacemaker).
  • disease requiring active treatment, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Specific instances of autoimmune disease are eligible and allowed on study, as below:

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone
    • Patients with controlled type 1 diabetes mellitus on a stable insulin regimen.
    • Patients with eczema or psoriasis with dermatologic manifestations only, provided that the disease is well controlled at baseline and only requiring topical , with no acute exacerbations within the last 12 months (requiring psoralen, ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan.
  • Chronic oral steroid use (greater than prednisone 10 mg orally once daily, or its equivalent) for any indication.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Safety lead-in: Chemoradiation + Durvalumab

    * The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events. * Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will be administered every 2 weeks or 4 weeks (timeline at the discretion of treating physician) for up to 12 months.

    Device: ViewRay MR-Linear Accelerator · Radiation: Radiation therapy · Drug: Paclitaxel · Drug: Carboplatin AUC · Biological: Durvalumab

  • Experimental
    Phase II: Chemoradiation + Durvalumab

    -Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will be administered every 2 weeks or 4 weeks (timeline at the discretion of the treating physician) for up to 12 months.

    Device: ViewRay MR-Linear Accelerator · Radiation: Radiation therapy · Drug: Paclitaxel · Drug: Carboplatin AUC · Biological: Durvalumab

Interventions

  • DeviceViewRay MR-Linear Accelerator

    -Radiation will be delivered by this machine

  • RadiationRadiation therapy

    -60Gy in 15 fractions

  • -50 mg/m\^2 intravenous

    Also known as: Taxol

  • DrugCarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    -2 mg/mL/min intravenous over 30 minutes

    Also known as: Paraplatin

  • BiologicalDurvalumab

    -10 mg/kg

    Also known as: Imfinzi

06

What researchers measure

Primary outcomes

  1. Safety lead-in Only: Number of Participants With Dose Limiting Toxicities (DLTs)

    * Safety of hypofractionated MRI-guided adaptive radiotherapy (60Gy/15 fractions) with concurrent chemotherapy (carboplatin and paclitaxel) and consolidation durvalumab is defined as \<2/6 participants experiencing dose limiting toxicities * DLT is defined as any possibly, probably, or definitely related to concurrent chemoradiation grade 3 toxicity that cannot be managed with maximal supportive care within 2 weeks, or any grade \> 4 toxicity that occurs during treatment * The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.

    Time frame: Through 6 months after completion of concurrent chemoradiation (estimated to be 6 months and 3 weeks)

  2. Local Control Rate

    -Defined as percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the primary (local) site

    Time frame: Through completion of follow-up (median 731 days, full range: 72 days-1162 days)

  3. Regional Control Rate

    -Defined as the percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the previously involved or uninvolved hilar and/or mediastinal nodal (regional) sites

    Time frame: Through completion of follow-up (median time 731 days, full range: 72 - 1162 days)

Secondary outcomes

  1. Number of Participants With Acute Toxicities by Worst Grade Experienced

    -Graded per NCI CTCAE version 5.0

    Time frame: From start of chemoradiation through 60 days

  2. Number of Participants With Late Toxicities by Worst Grade Experienced

    Graded per NCI CTCAE version 5.

    Time frame: From 61 days after start of chemoradiation through 2 years after the start of chemoradiation

  3. Tumor Response Rate

    -Tumor response is defined as achieving a partial or complete response per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Through completion of treatment (estimated to be 12 months and 3 weeks)

  4. Distant Control Rate

    -Defined as the number of participants who did not have distant recurrence. Distant recurrence is defined as the development of metastatic, non-local, and non-regional disease.

    Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)

  5. Incidence of Brain Metastases

    -Defined as the percentage of participants who develop brain metastases.

    Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)

  6. Median Progression-free Survival (PFS) Probability

    * PFS is defined as the months from start date of chemoradiation to either date of progression or death, whichever occurs first. Alive patients without progression are censored at the date of last follow-up or visit. * Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

    Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)

  7. Median Disease-free Survival (DFS) Probability

    DFS is defined as survival with no evidence of recurrent (local, regional or distant) disease or death

    Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)

  8. Median Overall Survival (OS) Probability

    OS is defined as the months from the start date of chemoradiation to the date of death. Alive patients are censored at the date of last follow-up or visit.

    Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)

07

Results

Posted Oct 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneSafety lead-in: Chemoradiation + DurvalumabPhase II: Chemoradiation + Durvalumab
Started620
Completed15
Not completed515
Withdrew: Adverse event37
Withdrew: Disease progression26
Withdrew: Withdrawal by subject01
Withdrew: Death01

Outcome measures

PrimarySafety lead-in Only: Number of Participants With Dose Limiting Toxicities (DLTs)

* Safety of hypofractionated MRI-guided adaptive radiotherapy (60Gy/15 fractions) with concurrent chemotherapy (carboplatin and paclitaxel) and consolidation durvalumab is defined as \<2/6 participants experiencing dose limiting toxicities * DLT is defined as any possibly, probably, or definitely related to concurrent chemoradiation grade 3 toxicity that cannot be managed with maximal supportive care within 2 weeks, or any grade \> 4 toxicity that occurs during treatment * The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.

Time frame:
Through 6 months after completion of concurrent chemoradiation (estimated to be 6 months and 3 weeks)
Reported as:
Count of participants · Participants
Safety lead-in Only: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsSafety lead-in: Chemoradiation + Durvalumab
Safety lead-in Only: Number of Participants With Dose Limiting Toxicities (DLTs)0
PrimaryLocal Control Rate

-Defined as percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the primary (local) site

Time frame:
Through completion of follow-up (median 731 days, full range: 72 days-1162 days)
Reported as:
Count of participants · Participants
Local Control Rate
ParticipantsChemoradiation + Durvalumab
Local Control Rate22
PrimaryRegional Control Rate

-Defined as the percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the previously involved or uninvolved hilar and/or mediastinal nodal (regional) sites

Time frame:
Through completion of follow-up (median time 731 days, full range: 72 - 1162 days)
Reported as:
Count of participants · Participants
Regional Control Rate
ParticipantsChemoradiation + Durvalumab
Regional Control Rate24
SecondaryNumber of Participants With Acute Toxicities by Worst Grade Experienced

-Graded per NCI CTCAE version 5.0

Time frame:
From start of chemoradiation through 60 days
Reported as:
Count of participants · Participants
Number of Participants With Acute Toxicities by Worst Grade Experienced
ParticipantsChemoradiation + Durvalumab Every 2 WeeksChemoradiation + Durvalumab Every 4 Weeks
Grade 1/2 Anemia20
Grade 3/4/5 Supraventricular tachycardia10
Grade 1/2 Constipation20
Grade 1/2 Diarrhea10
Grade 1/2 Dyspepsia21
Grade 1/2 Dysphagia21
Grade 1/2 Esophagitis82
Grade 3/4/5 Esophagitis10
Grade 1/2 Nausea31
Grade 1/2 Vomiting01
Grade 1/2 Fatigue31
Grade 1/2 Chest Heaviness10
Grade 1/2 Non-cardiac chest pain20
Grade 1/2 Pain10
Grade 3/4/5 Pain10
Grade 3/4/5 Urinary tract infection10
Grade 1/2 Bruising10
Grade 1/2 Fall10
Grade 1/2 Creatine increased10
Grade 1/2 Lymphocyte count decreased31
Grade 3/4/5 Lymphocyte count decreased112
Grade 1/2 Neutrophil count decreased20
Grade 3/4/5 Neutrophil count decreased10
Grade 1/2 Platelet count decreased10
Grade 1/2 White blood cell decreased30
Grade 3/4/5 White blood cell decreased20
Grade 1/2 Anorexia10
Grade 1/2 Dehydration20
Grade 1/2 Hyperglycemia10
Grade 3/4/5 Hyperglycemia10
Grade 1/2 Hyponatremia20
Grade 3/4/5 Hyponatremia10
Grade 1/2 Arthralgia20
Grade 1/2 Back pain10
Grade 1/2 Neck Pain10
Grade 1/2 Pain in extremity10
Grade 1/2 Headache20
Grade 1/2 Anxiety10
Grade 1/2 Insomnia20
Grade 3/4/5 Aspiration10
Grade 1/2 Cough10
Grade 1/2 Dyspnea10
Grade 1/2 Oropharyngeal pain10
Grade 1/2 Pneumonitis10
Grade 3/4/5 Respiratory failure10
Grade 1/2 Rash maculo-papular10
Grade 3/4/5 Hypertension10
Grade 3/4/5 Thromboembolic event10
SecondaryNumber of Participants With Late Toxicities by Worst Grade Experienced

Graded per NCI CTCAE version 5.

Time frame:
From 61 days after start of chemoradiation through 2 years after the start of chemoradiation
Reported as:
Count of participants · Participants
Number of Participants With Late Toxicities by Worst Grade Experienced
ParticipantsChemoradiation + Durvalumab Every 2 WeeksChemoradiation + Durvalumab Every 4 Weeks
Grade 1/2 Anemia10
Grade 3/4/5 Pericardial effusion10
Grade 1/2 Sinus tachycardia10
Grade 1/2 Hypothyroidism10
Grade 1/2 Abdominal distension10
Grade 1/2 Diarrhea10
Grade 1/2 Dyspepsia10
Grade 1/2 Dysphagia10
Grade 3/4/5 Esophageal stenosis10
Grade 3/4/5 Death NOS10
Grade 3/4/5 Death due to disease progression51
Grade 1/2 Fatigue21
Grade 1/2 Fever10
Grade 1/2 Non-cardiac chest pain20
Grade 1/2 Pain10
Grade 3/4/5 Pain10
Grade 3/4/5 Cholecystitis10
Grade 3/4/5 Hepatic failure10
Grade 3/4/5 COVID-1910
Grade 1/2 Lung infection10
Grade 3/4/5 Lung infection30
Grade 3/4/5 Osteomyelitis10
Grade 1/2 Skin infection10
Grade 1/2 Upper respiratory infection10
Grade 3/4/5 Dog Bite10
Grade 3/4/5 Fall01
Grade 1/2 Alanine aminotransferase increased10
Grade 1/2 Creatine increased20
Grade 3/4/5 Bicytopenia10
Grade 1/2 Lymphocyte count decreased41
Grade 3/4/5 Lymphocyte count decreased31
Grade 1/2 Weight loss20
Grade 1/2 White blood cell decreased10
Grade 3/4/5 White blood cell decreased10
Grade 3/4/5 Hypercalcemia10
Grade 1/2 Hyperglycemia10
Grade 1/2 Hyponatremia10
Grade 3/4/5 Hyponatremia10
Grade 1/2 Arthritis20
Grade 1/2 Back pain20
Grade 3/4/5 Back pain10
Grade 1/2 Generalized muscle weakness01
Grade 1/2 Muscle cramp10
Grade 1/2 Muscle weakness upper limb10
Grade 1/2 Ataxia10
Grade 1/2 Headache10
Grade 3/4/5 Seizure10
Grade 1/2 Anxiety10
Grade 1/2 Confusion11
Grade 3/4/5 Confusion10
Grade 1/2 Cough20
Grade 1/2 Dyspnea41
Grade 3/4/5 Dyspnea30
Grade 1/2 Nasal congestion10
Grade 1/2 Pleural effusion10
Grade 3/4/5 Pleural effusion10
Grade 1/2 Pneumonitis32
Grade 3/4/5 Pneumonitis20
Grade 3/4/5 Pneumothorax10
Grade 3/4/5 Respiratory failure10
Grade 3/4/5 Pulmonary nodular amyloidosis10
Grade 3/4/5 Cough with hemoptysis10
Grade 1/2 Sore throat10
Grade 1/2 Wheezing10
Grade 1/2 Hypertension10
Grade 3/4/5 Hypertension01
Grade 1/2 Lymphedema10
Grade 3/4/5 Thromboembolic event30
SecondaryTumor Response Rate

-Tumor response is defined as achieving a partial or complete response per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Through completion of treatment (estimated to be 12 months and 3 weeks)
Reported as:
Count of participants · Participants
Tumor Response Rate
ParticipantsChemoradiation + Durvalumab
Tumor Response Rate7
SecondaryDistant Control Rate

-Defined as the number of participants who did not have distant recurrence. Distant recurrence is defined as the development of metastatic, non-local, and non-regional disease.

Time frame:
Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Reported as:
Number · percentage of participants
Distant Control Rate
percentage of participantsChemoradiation + Durvalumab
Distant Control Rate61.54 (42.53 to 77.57)
SecondaryIncidence of Brain Metastases

-Defined as the percentage of participants who develop brain metastases.

Time frame:
Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Reported as:
Number · percentage of participants
Incidence of Brain Metastases
percentage of participantsChemoradiation + Durvalumab
Incidence of Brain Metastases15.38 (6.15 to 33.53)
SecondaryMedian Progression-free Survival (PFS) Probability

* PFS is defined as the months from start date of chemoradiation to either date of progression or death, whichever occurs first. Alive patients without progression are censored at the date of last follow-up or visit. * Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Time frame:
Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Reported as:
Median · months
Median Progression-free Survival (PFS) Probability
monthsChemoradiation + Durvalumab
Median Progression-free Survival (PFS) Probability8.84 (5.98 to NA)
SecondaryMedian Disease-free Survival (DFS) Probability

DFS is defined as survival with no evidence of recurrent (local, regional or distant) disease or death

Time frame:
Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Reported as:
Median · months
Median Disease-free Survival (DFS) Probability
monthsChemoradiation + Durvalumab
Median Disease-free Survival (DFS) Probability8.84 (5.98 to NA)
SecondaryMedian Overall Survival (OS) Probability

OS is defined as the months from the start date of chemoradiation to the date of death. Alive patients are censored at the date of last follow-up or visit.

Time frame:
Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Reported as:
Median · months
Median Overall Survival (OS) Probability
monthsChemoradiation + Durvalumab
Median Overall Survival (OS) Probability29.6 (19.94 to NA)

Adverse events

Collected over Acute toxicities/adverse events are followed from start of treatment through 60 days. Late toxicities/adverse events are followed from 61 days from start of chemoRT up to 2 years. All-cause mortality was collected from start of treatment to death from any cause or completion of study follow-up (median time 731 days, full range 72-1162 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemoradiation + Durvalumab Every 2 Weeks12/22 (54.5%)17/22 (77.3%)22/22 (100%)
Chemoradiation + Durvalumab Every 4 Weeks2/4 (50%)3/4 (75%)4/4 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventChemoradiation + Durvalumab Every 2 WeeksChemoradiation + Durvalumab Every 4 Weeks
Death due to disease progressionGeneral disorders5/221/4
FallInjury, poisoning and procedural complications0/221/4
ConfusionPsychiatric disorders2/221/4
DyspneaRespiratory, thoracic and mediastinal disorders4/220/4
Lung infectionInfections and infestations3/220/4
Thromboembolic eventVascular disorders3/220/4
Back painMusculoskeletal and connective tissue disorders2/220/4
PneumonitisRespiratory, thoracic and mediastinal disorders2/220/4
PneumothoraxRespiratory, thoracic and mediastinal disorders2/220/4
Respiratory failureRespiratory, thoracic and mediastinal disorders2/220/4
Most frequent other events
Showing 10 of 72
Most frequent other events
EventChemoradiation + Durvalumab Every 2 WeeksChemoradiation + Durvalumab Every 4 Weeks
Acute - Lymphocyte count decreasedInvestigations14/223/4
Acute - EsophagitisGastrointestinal disorders9/222/4
Late - Lymphocyte count decreasedInvestigations7/222/4
Late - PneumonitisRespiratory, thoracic and mediastinal disorders3/222/4
Acute - DyspepsiaGastrointestinal disorders2/221/4
Acute - DysphagiaGastrointestinal disorders2/221/4
Acute - NauseaGastrointestinal disorders3/221/4
Acute - VomitingGastrointestinal disorders0/221/4
Acute - FatigueGeneral disorders3/221/4
Late - FatigueGeneral disorders1/221/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Safety lead-in: Chemoradiation + DurvalumabPhase II: Chemoradiation + DurvalumabTotal
Mean65.8 (61 to 73)67.1 (57 to 79)66.8 (57 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Safety lead-in: Chemoradiation + DurvalumabPhase II: Chemoradiation + DurvalumabTotal
Female3912
Male31114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Safety lead-in: Chemoradiation + DurvalumabPhase II: Chemoradiation + DurvalumabTotal
Hispanic or Latino011
Not Hispanic or Latino61925
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety lead-in: Chemoradiation + DurvalumabPhase II: Chemoradiation + DurvalumabTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American134
White51722
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Safety lead-in: Chemoradiation + DurvalumabPhase II: Chemoradiation + DurvalumabTotal
United States62026
08

Study locations

1 site
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Sep 2025, 75 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 75 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 16, 2019
StartActual
Jun 20, 2019
Primary completionActual
Sep 28, 2025
CompletionActual
Sep 28, 2025
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedSafety lead-in onlyOnly: Number of participants with dose limiting toxicitiesParticipants With Dose Limiting Toxicities (DLTs)Time frame: Through 6 months after completion of concurrent chemoradiation (estimated to be 6 months and 3 weeks)
  • EditedLocal control rate (Phase II only)Control RateTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days-1162 days)
  • EditedRegional control rate (Phase II only)Control RateTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median time 731 days, full range: 72 - 1162 days)
Oct 6, 2026
Secondary outcomes
8 edited
What changed in the outcomes
  • EditedNumber of acute toxicitiesParticipants With Acute Toxicities by Worst Grade ExperiencedTime frame: From start of chemoradiation through 60 days
  • EditedNumber of late toxicitiesParticipants With Late Toxicities by Worst Grade ExperiencedTime frame: From 61 days after start of chemoradiation through 2 years after the start of chemoradiation
  • EditedTumor response rateResponse RateTime frame: Through completion of treatment (estimated to be 12 months and 3 weeks)
  • EditedDistant recurrence rateControl RateTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
  • EditedIncidence of brain metastasesBrain MetastasesTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
  • EditedMedian Progression-free survivalSurvival (PFS) ProbabilityTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
  • EditedMedian Disease-free survivalSurvival (DFS) ProbabilityTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
  • ChangedBefore Overall survivalNow Median Overall Survival (OS) ProbabilityTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedSafety lead-in onlyOnly: Number of participants with dose limiting toxicitiesParticipants With Dose Limiting Toxicities (DLTs)Time frame: Through 6 months after completion of concurrent chemoradiation (estimated to be 6 months and 3 weeks)
    • EditedLocal control rate (Phase II only)Control RateTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days-1162 days)
    • EditedRegional control rate (Phase II only)Control RateTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median time 731 days, full range: 72 - 1162 days)
    Secondary outcomes 8 edited
    What changed in the outcomes
    • EditedNumber of acute toxicitiesParticipants With Acute Toxicities by Worst Grade ExperiencedTime frame: From start of chemoradiation through 60 days
    • EditedNumber of late toxicitiesParticipants With Late Toxicities by Worst Grade ExperiencedTime frame: From 61 days after start of chemoradiation through 2 years after the start of chemoradiation
    • EditedTumor response rateResponse RateTime frame: Through completion of treatment (estimated to be 12 months and 3 weeks)
    • EditedDistant recurrence rateControl RateTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
    • EditedIncidence of brain metastasesBrain MetastasesTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
    • EditedMedian Progression-free survivalSurvival (PFS) ProbabilityTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
    • EditedMedian Disease-free survivalSurvival (DFS) ProbabilityTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
    • ChangedBefore Overall survivalNow Median Overall Survival (OS) ProbabilityTime frame: Through 2 years after start of chemoradiation (estimated to be 2 years and 3 weeks) → Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
    + 3 other changes: verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03916419
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Jun 20, 2019
Primary completion
Sep 28, 2025
Completion
Sep 28, 2025
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Gregory Vlacich, M.D, Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion